Menu
/REGISTER
Montecito
Nixon Peabody
Chase
Bank of America
Loading...
You are here:  Home  >  Biotech  >  Current Article

Amgen seeks license for biosimilar version of oncology drug Rituxan

By   /   Thursday, December 19th, 2019  /   Comments Off on Amgen seeks license for biosimilar version of oncology drug Rituxan

    Print       Email
On the heels of its third U.S. approval for a biosimilar, Amgen submitted an application to regulators for an oncology drug imitating Rituxan, a $5 billion drug made by Roche. The Thousand Oaks biotech giant said it submitted a biologics license application to the U.S. Food and Drug Administration for its product ABP 798 in…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Movegreen makes LA, Orange County acquisitions

Read More →